Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

September 13, 2019September 13, 2019

FDA to Review Nerlynx Combo as Third-line Treatment for HER2-positive Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review Puma Biotechnology’s application seeking approval of Nerlynx (neratinib), in combination with capecitabine, to treat HER2-positive breast cancer patients with metastatic disease, ... Read more

September 9, 2019September 9, 2019

Nerlynx Granted FDA’s Orphan Drug Status for Treating Breast Cancer with Brain Metastases

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Puma Biotechnology’s Nerlynx (neratinib) for the treatment of HER2-positive breast cancer in women with brain metastases. Between 10 to 15% ... Read more

August 19, 2019

Phase 2 Trial of NeuVax Vaccine for HER2-positive DCIS Fully Enrolled, Sellas Announces

News

The Phase 2 trial evaluating Sellas Life Sciences‘ cancer vaccine NeuVax as a treatment for women with early stage HER2-positive ductal carcinoma in situ (DCIS), a non-invasive breast cancer, has ... Read more

August 16, 2019

Trial Testing Eftilagimod Alpha-Chemo Combo for HR-positive Advanced Breast Cancers Now Fully Enrolled

News

Immunotep has completed patient enrollment for its Phase 2b trial evaluating eftilagimod alpha (IMP321) — an investigational therapy that stimulates the immune system to fight cancer — in combination ... Read more

July 29, 2019July 29, 2019

Anixa Partners with Cleveland Clinic to Take Breast Cancer Vaccine to Human Trials

News

Anixa Biosciences, a leading company developing anti-cancer immunotherapies, is partnering with the Cleveland Clinic to advance a vaccine against triple-negative breast cancer (TNBC) to testing in humans. “We are ... Read more

July 3, 2019

CHMP Recommends Tecentriq-Abraxane Combination to Treat Some Triple-negative Breast Cancers in Europe

News

The  Committee for Medicinal Products for Human Use (CHMP),  an arm of the  European Medicines Agency , has recommended the approval of Tecentriq (atezolizumab) in combination with the chemotherapy Abraxane (nab-paclitaxel) as ... Read more

June 21, 2019

Anti-Diarrheal Medicines Improve Tolerability of Nerlynx in Breast Cancer Patients

News

Severe diarrhea is a side effect experienced by more than one-third of women with HER2-positive early-stage breast cancer receiving secondary treatment with Nerlynx (neratinib). But preventive treatment with loperamide ... Read more

May 10, 2019

Kadcyla Approved in US for Some HER2-positive Early Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has extended the use of Genentech‘s Kadcyla (ado-trastuzumab emtansine) as an adjuvant (post-surgery) treatment for some patients with HER2-positive, early-stage breast cancer, the company ... Read more

April 29, 2019April 29, 2019

Clinical Trial Will Test Investigational Therapy Targeting ‘Dormant’ Breast Cancer Cells

News

GlycoMimetics is planning a clinical trial testing its therapy candidate GMI-1359 as a treatment for breast cancer patients whose tumors have spread to the bones, the company announced. GMI-1359 ... Read more

April 24, 2019

Liposomal Irinotecan Shows Promising Phase 1 Results in Heavily Treated Breast Cancer Patients

News

Treatment with a liposomal formulation of irinotecan — meaning the chemotherapy is wrapped up in tiny fatty spheres —was well-tolerated and partially reduced the tumor burden in 35% of ... Read more

Pin It on Pinterest